Proficient Detection of Multi-Drug-Resistant ... - ACS Publications

Subscriber access provided by MAHIDOL UNIVERSITY (UniNet)

Article

Proficient detection of multidrug-resistant Mycobacterium tuberculosis by padlock probes and lateral flow nucleic acid biosensors Pavankumar R Asalapuram, Anna Engström, Jie Liu, David Herthnek, and Mats Nilsson Anal. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.analchem.5b04312 • Publication Date (Web): 17 Mar 2016 Downloaded from http://pubs.acs.org on March 18, 2016

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Analytical Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 21

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Analytical Chemistry

1

Proficient detection of multidrug-resistant Mycobacterium tuberculosis by padlock

2

probes and lateral flow nucleic acid biosensors

3 4

Asalapuram R Pavankumar, Anna Engström§, Jie Liu#, David Herthnek, Mats Nilsson*

5 6

Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm

7

University, Stockholm, Sweden.

8 9 10 11 12 13 14 15 16 17

--------------------------------------------------------------------------------------------------------------

18

*Corresponding author: Mats Nilsson, Science for Life Laboratory, Department of

19

Biochemistry and Biophysics, Stockholm University, Box 1031, SE-17121 Stockholm,

20

Sweden. E-mail: [email protected]; Phone: +46 (0)762 756 161.

21

Present address:

22

University, Uppsala, Sweden and Molecular and Experimental Mycobacteriology, Research

23

Center Borstel, Borstel, Germany, #School of Chinese Medicine, Hong Kong Baptist

24

University, China.

§

Department of Medical Biochemistry and Microbiology, Uppsala

25

ACS Paragon Plus Environment

1


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 2 of 21

26

Abstract

27

Tuberculosis is a major communicable disease. Its causative agent, Mycobacterium

28

tuberculosis, becomes resistant to antibiotics by acquisition of point mutations in the

29

chromosome. Multidrug-resistant tuberculosis (MDR-TB) is an increasing public health

30

threat and prompt detection of such strains is of critical importance. As rolling circle

31

amplification of padlock probes can be used to robustly distinguish single-nucleotide

32

variants, we combined this technique with a sensitive lateral flow nucleic acid biosensor to

33

develop a rapid molecular diagnostic test for MDR-TB. A proof-of-concept test was

34

established for detection of the most common mutations [rpoB 531 (TCG/TTG) and katG 315

35

(AGC/ACC)] causing MDR-TB and verification of loss of the respective wild type. The

36

molecular diagnostic test produces visual signals corresponding to the respective genotypes

37

on lateral flow strips in approximately 75 min. By detecting only two mutations, the test can

38

detect about 60% of all MDR-TB cases. The padlock probe-lateral flow (PLP-LF) test is the

39

first of its kind and can ideally be performed at resource-limited clinical laboratories. Rapid

40

information about the drug-susceptibility pattern can assist clinicians to choose suitable

41

treatment regimens and take appropriate infection control actions rather than prescribing

42

empirical treatment, thereby helping to control the spread of MDR-TB in the community.

43 44 45 46 47 48 49 50


2

Page 3 of 21

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


51

Introduction

52

Tuberculosis (TB) is a major infectious disease causing 9 million new cases and 1.5 million

53

deaths per year.1 The causative agent of TB, Mycobacterium tuberculosis (MTB), develops

54

drug resistance by acquisition of mutations in the chromosome.2 MTB strains resistant to at

55

least the two major first line anti-TB drugs isoniazid (INH) and rifampicin (RIF) are

56

classified as multidrug resistant TB (MDR-TB). According to the 2014 WHO Global

57

Tuberculosis Report, 3.5% of new and 20.5% of previously treated cases are infected with

58

MDR-TB strains and the prevalence is expected to increase. MDR-TB treatment is very

59

complicated and involves the use of more toxic drugs with prolonged treatment duration from

60

months to years. Recently the TBNET and RESIST-TB networks suggested that the

61

identification of MTB mutations in clinical isolates coding for katG, inhA, rpoB, embB, rrs,

62

rpsL and gyrA has implications for the management of TB patients, pending the results of in

63

vitro DST.3 Therefore, improved infection control measures and better diagnostic methods

64

are needed to reduce the spread of MDR-TB strains. Correct identification of MDR-TB

65

isolates remains a challenge for resource-limited clinical laboratories due to high cost of

66

sample processing. Therefore, there is an urgent need of robust and inexpensive MDR-TB

67

diagnostic test methods suitable for resource limited peripheral laboratories to facilitate

68

initiation of early and effective treatment.

69 70

Generally, MTB is primarily detected by smear microscopy, which is a relatively cheap and

71

rapid method. However, it cannot identify drug-resistant strains. Culture-based methods for

72

phenotypic drug susceptibly testing (DST), on the other hand, are laborious and time-

73

consuming, requiring weeks to months to obtain results due to the slow growth of MTB.4 In

74

contrast, polymerase chain reaction (PCR) based nucleic acid amplification tests (NAAT)

75

provide rapid results for the detection of drug-resistant MTB strains through various


3


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 4 of 21

76

automated and semi-automated techniques. For example, the GeneXpert MTB/RIF (Cepheid,

77

Sunnyvale, CA, USA) provides rapid indicative identification of MDR-TB directly from

78

sputum samples in less than 2 hours.5 However, it is restricted to only specific detection of

79

RIF resistance. The probe-hybridization assay, GenoType MTBDRplus (Hain Lifescience

80

GmbH, Nehren, Germany) can detect MDR-TB,6 but requires multiple manual steps and

81

specific instruments. Although the solid-phase reverse hybridization line-probe assay (LPA)

82

can rapidly detect RIF and INH resistance, it is not recommended by WHO for the detection

83

of second-line drug-resistance attributes.7-8 Conclusively, the capacity and requirement for

84

instrumentation and skilled personnel of currently available NAATs hinder prompt detection

85

of MDR-TB in resource-limited settings. Therefore, a proficient method that can address the

86

molecular detection challenges of MDR-TB and be implemented in peripheral laboratory

87

settings is required to provide easily interpreted first-hand information about MDR-TB

88

isolates.

89 90

In the light of the need of rapid diagnostic methods, the use of lateral flow nucleic acid

91

biosensors (LFNAB) becomes an excellent choice, on which immobilized antibodies or

92

nucleic acid tags on a nitrocellulose membrane specifically bind to their corresponding

93

antigens or nucleic acid targets. The visual signals (color change) are usually developed on

94

the lateral flow (LF) strips by means of hybridization of substrates like streptavidin, biotin,

95

horseradish peroxidase, or conjugated gold nanoparticles (AuNP).9-10 Generally, the target

96

molecules are amplified by an isothermal NAAT,11 and in case of drug-resistant TB, the

97

main challenge lies in the correct identification of point mutations. Among several potential

98

isothermal amplification methods, rolling circle amplification (RCA) in combination with

99

target recognition by padlock probes (PLPs) is one of the most promising technologies that

100

enable accurate detection of single nucleotide variants, even in a highly multiplexed


4

Page 5 of 21

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


101

fashion.12 PLPs are linear oligonucleotide probes that enable mutation detection by ligation-

102

dependent circularization.13-15 As the probe ends hybridize in juxtaposition on the target

103

specific site, a perfect match at the 3’ end is required for ligation, efficiently discriminating

104

point mutations.16 The linker segment in the middle contains sequences with functions for

105

amplification, identification and detection. The circularized padlock can undergo RCA to

106

produce a single-stranded concatemer, containing multiple complementary repeats of the PLP

107

sequence. In order to improve the sensitivity, the concatemer is restriction digested, re-ligated

108

into new circles and subjected to an additional round of RCA, known as circle-to-circle

109

amplification (C2CA).17 Requirement of sophisticated instruments like fluorometers,

110

fluorescence microscopes, array scanners, etc. to read out C2CA signals hamper the use of

111

RCA in resource-limited laboratories and calls for alternative methods.

112 113

Earlier, we have developed a molecular method for the multiplex detection of RIF-resistant

114

MTB based on padlock probes and magnetic nanobeads.18 However, due to the singleplex

115

nature of the applied readout, wild type confirmation and species identification had to be

116

performed in different reaction tubes. Considering the advantages of RCA in molecular

117

diagnostics, especially to discriminate the single nucleotide variants in drug-resistant MTB,

118

we have previously combined the method with LFNAB to produce multiplex qualitative

119

color signals for the identification of INH-resistance targeting katG 315 mutation. In this

120

study, we present the proof-of-concept for a simple, specific and cost-effective diagnostic

121

PLP-LF test for the prompt identification of MDR-TB from primary cultures. The DNA-

122

based test was developed for the application in resource-limited clinical laboratories that

123

gives a conception about the drug resistance pattern of both INH and RIF, which would be

124

very valuable for clinicians in order to take appropriate actions for treatment and infection

125

control.


5


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 6 of 21

126

Experimental section

127

Chemicals and oligonucleotides

128

Streptavidin from Streptomyces avidinii, gold(III)chloride trihydrate (HAuCl4), sucrose,

129

dithiothreitol (DTT), Triton X-100, trisodium citrate, Tris(hydroxymethyl)aminomethane

130

hydrochloride (Tris-HCl), Tween 20, Ethylenediaminetetraacetic acid (EDTA) and bovine

131

serum albumin (BSA, for oligonucleotide-AuNP conjugates) were purchased from Sigma-

132

Aldrich (St. Louis, MO, USA). Sodium chloride-sodium citrate (SSC) buffer (pH 7.0),

133

phosphate buffer saline (PBS, pH 7.4, 0.01 M), and sodium chloride (NaCl, 5 M, pH 7.0)

134

were purchased from Substratenheten at Klinisk mikrobiologi, Karolinska University hospital

135

(Stockholm, Sweden). ATP and dNTP were purchased from Thermo Scientific (Waltham,

136

MA, USA). All oligonucleotides were purchased from Integrated DNA Technologies

137

(Leuven, Belgium) and Sigma-Aldrich. For the LF assay, binder-free borosilicate glass fiber

138

pads (grade A/C), cellulose fiber absorbent pads (grade 113) and nitrocellulose membrane

139

(BioTrace™ NT) attached to the laminated cards/strips (0.4 and 0.5 cm width) were

140

purchased from Kinbio Tech (PuDong, Shanghai, China).

141 142

Bacterial strains and DNA extraction

143

The reference strain MTB H37Rv (ATCC 25618) and ten clinical MTB isolates (Table 1),

144

previously genotyped by Engström et al.,19 were cultured on Löwenstein-Jensen medium with

145

and without 40 mg/L of RIF, respectively. DNA was extracted according to Juréen et al.,20

146

and 10 µg of genomic DNA was fragmented enzymatically using 10 U each of NaeI and

147

HpyCH4V, and 1x CutSmart buffer (New England Biolabs, Ipswich, MA, USA) at 37°C for

148

90 min followed by enzyme inactivation at 65°C for 20 min. DNA concentration was

149

measured by the dsDNA HS and BR assays using Qubit 2.0 fluorometer (Life Technologies,

150

Carlsbad, CA, USA).


6

Page 7 of 21

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


151

Padlock probes and rolling circle amplification

152

Sequences of oligonucleotides used in this study are given in Table 2. Four PLPs were

153

designed to target two codons in the genes katG and rpoB and their corresponding wild type

154

sequences (katG 315 ACC (MUT), katG 315 AGC (WT), rpoB 531 TTG (MUT) and rpoB

155

531 TCG (WT). Secondary structure predictions were analyzed using Mfold Web Server.21

156

The PLPs were phosphorylated at the 5’ end by incubating a reaction mixture consisting of 1

157

µM oligonucleotide, 1x PNK buffer A, 1 mM ATP), and 1 U/µl T4 polynucleotide kinase

158

(Thermo Scientific, Waltham, MA, USA) at 37°C for 30 min, followed by enzyme

159

inactivation at 65°C for 20 min. Confirmation of PLP efficacy was done by performing

160

C2CA, according to Dahl et al.,17 with minor modifications: the coiled amplification products

161

produced from 1 amol of synthetic target was fluorescently labeled and quantified by

162

automated counting in a microfluidic cell under a confocal microscope (data not shown).22

163

Sensitivity of the assay was evaluated by LF strips with amplicons prepared from 300 pg, 3

164

ng, 30 ng and 300 ng of genomic DNA. The specificity of the PLPs were confirmed by

165

performing C2CA on 300 ng genomic DNA extracted from the strains in Table 1.

166 167

As depicted in Figure 1A, the C2CA assay procedure starts by hybridization and ligation at

168

60°C for 5 min in 20 µL of reaction mixture containing target DNA, 1x Ampligase buffer,

169

250 mU/µL Ampligase (EpiCenter, Madison, WI, USA), 0.2 µg/µL BSA, 33 nM of each of

170

the phosphorylated PLPs and 50 nM of each capture probe. Streptavidin-coated magnetic

171

beads (Dynabeads MyOne Streptavidin T1, Life Technologies, California, USA) were

172

washed three times in 1x Wtw buffer [10 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% Tween

173

20, 0.1 M NaCl] and ligated circles were coupled to 5 µl of these beads by means of the

174

biotinylated capture probes at room temperature (RT) for 5 min. Unreacted oligonucleotides

175

were removed by washing the beads once with 100 µl of 1x Wtw buffer and the buffer was


7


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 8 of 21

176

replaced by 20 µL of RCA mixture [0.2 µg/µL BSA, 125 µM dNTP, 1x Phi29 buffer and 100

177

mU/µL Phi29 DNA polymerase (Thermo Scientific, Waltham, MA, USA)]. RCA was

178

performed at 37°C for 20 min followed by enzyme inactivation at 65°C for 1 min. The single

179

stranded concatemers were monomerized by incubation in a digestion mixture consisting of

180

120 nM of restriction oligonucleotide S00244, 0.2 µg/µL BSA and 120 µU/µL of AluI (New

181

England Biolabs, Ipswich, MA, USA) and 1x Phi29 buffer followed by incubation at 37°C

182

for 5 min and enzyme inactivation at 65°C for 3 min. The beads were discarded and

183

monomerized RCA products were re-circularized and amplified again in 1x Phi29 buffer, 0.2

184

µg/µL BSA, 100 µM dNTP, 0.68 mM ATP, 60 mU/µL Phi29 DNA polymerase and 14

185

mU/µL T4 DNA ligase (Thermo Scientific, Waltham, MA, USA) at 37°C for 20 min,

186

followed by enzyme inactivation at 65°C for 1 min. For application on LF strips, the C2CA

187

concatemers were again monomerized by adding a digestion mixture [1.8 µM restriction

188

oligonucleotide S00166, 0.2 µg/µL BSA and 550 µU/µL AluI in 1x Phi29 buffer] at 37°C for

189

10 min, followed by enzymatic inactivation at 65°C for 3 min.

190 191

Preparation and characterization of oligonucleotide conjugated gold nanoparticles

192

Gold nanoparticles were prepared by a standard citrate reduction method with slight

193

modifications.9,23 In a dry 500 mL round-bottom borosilicate glass flask, cleaned in

194

aquaregia (nitric acid and hydrochloric acid in 3:1 ratio), 100 mL of 0.01% HAuCl4 in

195

MilliQ water was boiled with vigorous stirring. Four milliliters of 1% trisodium citrate

196

solution was added and after turning wine-red, the solution was boiled for 10 more min.

197

Heating was turned off and the AuNP-solution was allowed to gradually cool to RT and was

198

stored at 4°C, until further use.

199


8

Page 9 of 21

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


200

Fifty micromolar of thiolated oligonucleotide, designed to hybridize to a sequence present in

201

all C2CA monomers, was reduced by 500 mM of DTT in SSC buffer for 30 min at RT. A

202

NAP™-5 column (GE Healthcare Biosciences, Little Chalfont, UK) was equilibrated with

203

citrate buffer and the activated oligonucleotide was eluted directly into 1 mL of 4-fold

204

concentrated AuNPs. After gentle mixing, it was incubated for 2 h at 37°C and 50 µL of 1 M

205

NaCl was added with gentle agitation. It was kept for ‘aging’ at 4°C for 24 h and another 100

206

µL of 1 M NaCl was added. The solution was centrifuged at 13,000 g for 25 min, the

207

supernatant discarded and the AuNP-oligonucleotide conjugates re-dispersed in 1 mL of 5%

208

BSA, 0.25% Tween 20 and 20 mM Tris-HCl (pH 8.0) and filtered through a 0.2 µm syringe

209

filter (Merck Millipore KGaA, Darmstadt, Germany).

210 211

Conventional transmission electron microscope (TEM) images of the prepared AuNP were

212

obtained at 100 kV with low-dose procedures and magnifications of 50,000x and 300,000x

213

using JOEL JEM-2100 LaB6 microscope. The AuNP-oligonucleotide conjugates were

214

characterized by measuring their light absorption at 520 nm in a Multi-Mode Microplate

215

Reader (SpectraMax® M5, Molecular Devices). In addition, their size-distribution and

216

surface charge (ζ-potential) was measured in citrate buffer (pH 7.0) at 25°C by dynamic light

217

scattering (DLS) using Zetasizer Nano ZS90 (Malvern, UK) equipped with a 4.0 mW HeNe

218

laser and an avalanche photodiode detector.

219 220

Design, assembly and preparation of lateral flow strips

221

As depicted in Fig. 1B, the 100 x 5 mm LF strip consists of a sample application pad,

222

nitrocellulose membrane and absorbent pad that are mounted on a thin plastic backing. The

223

dry sample pad (25 x 5 mm) was saturated using saturation buffer (1% BSA, 1% Triton

224

X-100, 20 mM Tris-HCl, 100 mM NaCl; pH 8.0), air-dried and fixed on one end of the


9


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 10 of 21

225

nitrocellulose membrane (45 x 5 mm) with an overlap of 2-3 mm and the absorbent pad (30 x

226

5 mm) was fixed on the other end of the nitrocellulose membrane. The biotinylated strip

227

oligonucleotides (Table 2) were immobilized in test and control zones on the nitrocellulose

228

membrane. The control zone contained one line of immobilized oligonucleotides

229

complementary to the AuNP-oligonucleotide conjugates. The test zone contained 4 lines

230

separated by 3 mm, where each line consisted of unique strip oligonucleotides for detection

231

of the C2CA monomers corresponding to their specific genotypes of katG 315 WT, katG 315

232

MUT (AGC/ACC), rpoB 531 WT and rpoB 531 MUT (TCG/TTG) by hybridization (Fig.

233

1B). Fifty micromolar of the strip oligonucleotide was mixed with an equal volume of 1x

234

PBS containing 15 µM of streptavidin. After incubation at 37°C for 2 h, 3.9 nL of the

235

streptavidin-conjugated oligonucleotide was printed (immobilized) on the nitrocellulose

236

membrane using a nanoplotter (Nano-Plotter NP2.0, GeSiM, Grosserkmannsdorf, Germany).

237

The strips were incubated overnight at 37°C and stored in a dry place until further use.

238 239

Visualization of C2CA amplicons on lateral flow strips

240

Fifty-five microliters of the C2CA monomers were hybridized with 13 µL of AuNP-

241

oligonucleotide conjugates for 5 min at RT and applied to the sample pad of LF strips, drop

242

by drop. The sample was allowed to flow for 5-7 min and washed with 4x SSC buffer for

243

visualization of the red color bands. Color development in the control line indicated the

244

positive assay control, while the signals from each test line specifically referred to presence

245

of WT and/or MUT genotypes of katG 315 and rpoB 531. Intensity graphs were generated

246

for the bands and pixel-densities were measured to quantify the results in densitograms, using

247

the open source tool ImageJ (Version 1.49q).24

248 249


10

Page 11 of 21

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


250

Results and discussion

251

There is an urgent need for development of prompt and inexpensive diagnostic tests for the

252

correct identification of drug-resistant MTB strains. We aimed to develop a robust and

253

stringent molecular diagnostic method for screening of MDR-TB, by combining PLP-RCA

254

and LF biosensors. The test, as illustrated in the Fig. 1, is an assay format to produce rapid

255

visual signals to discriminate between wild type and the most common mutations in katG and

256

rpoB genes, causing MDR-TB, i.e. resistance to INH and RIF.

257 258

Figure 1. Proof-of-principle of the PLP-LF assay

259

The linker segment (grey) of the PLP contains detection and restriction sites, while the 5’ and

260

3’ arms (black) are designed to hybridize to the target sequence (orange; A). Upon matched


11


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 12 of 21

261

hybridization, PLPs are ligated and the circularized probes can undergo RCA. The amplicons

262

are digested using a restriction oligonucleotide. The products are again amplified by RCA

263

(C2CA), monomerized and hybridized in a sandwich fashion to their common tags of AuNP

264

oligonucleotides and to the respective WT or MUT oligonucleotide tags immobilized on the

265

LF strips to produce visual signals (B). Blue are the restriction oligonucleotides, which will

266

serve as templates to produce C2CA concatemers, which are further restriction digested to

267

apply on lateral flow strips. Visual signals are developed when the immobilized streptavidin-

268

bound oligonucleotides are hybridized to its respective C2CA monomers and thiolated

269

oligonucleotides conjugated with gold nanoparticles.

270 271

The method can produce visual signals in approximately 75 min and the results can guide

272

clinicians in taking informed decisions on public health control actions as well as adjusting to

273

an effective antibiotic regimen. Hence, the test could be a preliminary alternative to the time-

274

consuming conventional DST and offers a compatible solution for resource-limited clinical

275

laboratories.

276 277

Evaluation of AuNP-oligonucleotide conjugates

278

The TEM images of the AuNP (Fig. 2 A and B) confirm the size of sphered particles to be 15

279

± 3.5 nm. Size distribution curve based on the light absorption of AuNP showed a λ-max at

280

520 nm before oligonucleotide conjugation and the peak shifted to 527 nm after the

281

conjugation (Fig. 2C). However, the DLS measurements of AuNP-oligonucleotide conjugate

282

(Fig. 2D) revealed an average diameter of 90 ± 4 nm with a single peak indicating

283

monodispersed solution without particle aggregation. The ζ-potential measurements of -37.4

284

mV and -34.5 mV for AuNP and their oligonucleotide-conjugates, respectively, showed that

285

the preparations were stable.

286 287 288


12

Page 13 of 21

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


289 290

Figure 2. Analysis of gold nanoparticles and its oligonucleotide conjugates

291

Transmission electron microscopic (TEM) images at 50,000x and 300,000x magnification (A

292

and B) shows that the gold nanospheres have an average diameter of 15 ± 0.5 nm. A shift

293

light absorbance spectra (C) from 520 nm to 528 nm shows that the prepared gold particles

294

are conjugated with the oligonucleotides. Single smooth spectrum of DLS measurements (D)

295

confirms conjugation and monodispersion of the AuNP-oligonucleotide conjugates.

296 297

Limit of detection of padlock probe-lateral flow test

298

Limit of detection (LOD) of this PLP-LF assay was performed in triplicates by testing 10-

299

fold dilutions of extracted genomic DNA from the reference strain MTB H37Rv. Signal from

300

as little as 3 ng of DNA could be seen for the katG 315 WT probe, while at least 30 ng of


13


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 14 of 21

301

DNA was needed for the rpoB 531 WT probe. Since both signals were clearly observed with

302

300 ng of DNA (Fig. 3A), further experiments with DNA from clinical samples (Table 1)

303

were performed using this amount. Densitograms (Fig. 3B) based on the local pixel density

304

of red color signals developed on lateral flow strips correlated with the visual observation.

305 306

Figure 3. LOD of PLP-LF method

307

Limit of detection of the PLP-LF method was investigated by testing 10-fold dilutions of

308

genomic MTB DNA (A). The densitograms in B, plotted by computing the local color

309

intensities, depicts the semi-quantitative changes in the control and test lines.

310 311

The signal intensity of rpoB 531 WT was lower compared to katG 315 WT, which could be

312

due to the high GC content in the target region of the rpoB gene, potentially resulting in a

313

lower yield of C2CA monomers. Minor variations were observed among the densitograms of

314

control lines, even though the lateral flow strips from the same printing session were used.

315

Such differences can be expected in LF tests25 due to the accumulation of AuNP around the

316

printed spots, differences in absorbance or flow properties of nitrocellulose membrane or the

317

position of printed lines. These problems will be addressed by improving the flow kinetics in

318

future work to increase the sensitivity of the test. Another approach to achieve higher

319

sensitivity would involve the addition of another cycle of RCA to the assay,26 which could


14

Page 15 of 21

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

320


enable direct testing on sputum samples.

321 322

Visual evaluation of the padlock probe-lateral flow test on clinical isolates of MTB

323

A set of 10 clinical isolates MTB (Table 1) that were resistant and/or susceptible to INH and

324

RIF, were tested by the PLP-LF method. As seen in Fig. 4, five strains (ID numbers: 2, 4, 8,

325

9, and 12) contained mutant katG and rpoB codons; three strains (19, 20 and 21) possessed

326

only wild type codons and one strain (13) showed the presence of wild type katG codon but

327

mutant rpoB codon.

328

329 330

Figure 4. Testing MTB clinical isolates by PLP-LF method

331

Ten characterized genomic DNA samples (300 ng) isolated from clinical MTB containing

332

wild type or mutant codons of rpoB 531 and katG 315 were tested. The densitograms

333

qualitatively shows the presence and/or absence of wild type and/or mutant genotypes of the

334

clinical isolates.

335 336

While sample number 17 clearly showed a line corresponding to mutant katG codon, it did

337

not yield a result for the rpoB codon on any replicate of the strips. This inconclusive result

338

demonstrates the usefulness of including probes targeting wild type in the test, since a lack of


15


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 16 of 21

339

mutant rpoB 531 signals would otherwise have been interpreted as an indication of wild type

340

rpoB. All the other visual signals of PLP-LF assay of the tested strains were fully concordant

341

to genotypic characterization of the strains by pyrosequencing19 and the respective

342

densitograms below each LF strip correspond to their visual signals. The method could be

343

expanded by including a variety of other mutations causing MDR-TB, and the sensitivity

344

could be improved for application directly on sputum samples from TB patients.

345 346

Conclusion

347

Drug-resistant TB is an increasing global health problem and the identification of MDR-TB

348

remains a challenge. Culture-based DST and advanced NAATs can only be performed in

349

well-equipped laboratories or require expensive equipment. In general, DST reports of anti-

350

TB drugs would miss important information about the non-concordant resistance-associated

351

mutations. As suggested in the TBNET/RESIST-TB consensus statement-2016, identification

352

and provision of details about the MTB mutations causing drug-resistance in the genes like

353

katG, inhA, rpoB, embB, rrs, rpsL and gyrA would help the clinicians and health-care

354

professionals to take appropriate TB controlling measures. In order to establish such a robust

355

diagnostic method offering reliable initial screening of MDR-TB that is suitable for resource-

356

limited healthcare settings and peripheral clinical laboratories, we have developed a PLP-LF

357

assay. This unique and rapid test provides preliminary information about the most common

358

clinically significant mutations causing MDR-TB. Consequently, providing a valuable

359

preview of the drug-susceptibility pattern at the early stages of diagnosis could certainly help

360

clinicians to start treatment with appropriate antibiotics in as little as 75 min. In this proof-of-

361

concept study, we have included only the most prevalent mutations causing INH and RIF

362

resistance. This could be the first report of its kind to develop a visual detection test for the

363

prompt identification of MDR-TB isolates, which can be potentially expanded for the


16

Page 17 of 21

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


364

detection extensively drug-resistant TB (XDR-TB) in resource-limited laboratories and

365

peripheral laboratories.

366 367

Acknowledgements

368

This research was partially supported by an Indo-Swedish cooperative program of Swedish

369

Research Council (VR), the Swedish Governmental Agency for Innovation Systems

370

(Vinnova) and Innovative Medicines Initiative, a public-private partnership between the

371

European Union, and the European Federation of Pharmaceutical Industries and Associations

372

(RAPP-ID project, grant agreement, no. 115153). Authors thank German Salazar Alvarez,

373

(Institutionen för material- och miljökemi, Stockholm University) for helping with TEM

374

images, Teresa Zardań Gómez Torre (Department of Engineering Sciences, Nanotechnology

375

and Functional Materials, Uppsala University) for DLS measurements and Camilla Russell

376

(Dept. of Biochemistry and Biophysics, Stockholm University) for the useful technical

377

discussions and timely help.

378 379

Author Contributions

380

ARP, JL and MN conceived the concept; ARP, AE and LJ designed and performed the

381

experiments. ARP, AE, JL, DH and MN analyzed the data, and wrote the manuscript.

382 383

Conflict of interest

384

MN holds stock in Olink Bioscience AB that holds commercial rights to padlock probes.

385 386 387 388


17


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 18 of 21

389

Reference

390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437

(1) Pai, M.; Schito, M.; J. Infect. Dis. 2015, 211(S2), S21–28. (2) Ramaswamy, S. L.; Musser, J. M. J. Tuber. Lung. Dis. 1998, 79, 3-29. (3) Domínguez, J.; Boettger, E. C.; Cirillo, D.; Cobelens, F.; Eisenach, K. D.; Gagneux, S.; Hillemann, D.; Horsburgh, R.; Molina-Moya, B.; Niemann, S.; Tortoli, E.; Whitelaw, A.; Lange, C.; for the TBNET and RESIST-TB networks. Int. J. Tuberc. Lung. Dis. 2016, 20, 24–42. (4) Kim, S. J. Eur. Respir. J. 2005, 25, 564–569. (5) Helb, D.; Jones, M.; Story, E.; Boehme, C.; Wallace, E.; Ho, K.; Kop, J. A.; Owens, M. R.; Rodgers, R.; Banada, P.; Safi, H.; Blakemore, R.; Lan, N. T. N.; Jones-López, E. C.; Levi, M.; Burday, M.; Ayakaka, I.; Mugerwa, R. D.; McMillan, B.; Winn-Deen, E.; Christel, L.; Dailey, P.; Perkins, M. D.; Persing, D. H.; Alland, D. J. Clin. Microbiol. 2010, 48, 229-237. (6) Hillemann, D.; Rüsch-Gerdes, S.; Richter, E. J. Clin. Microbiol. 2007, 45, 2635-2640. (7) Wilson, M. L. Arch. Pathol. Lab. Med. 2013, 137, 812–819. (8) Theron, G.; Peter, J.; Richardson, M.; Barnard, M.; Donegan, S.; Warren, R.; Steingart, K. R.; Dheda, K. Cochrane. Database Syst. Rev. 2014, 10, CD010705. (9) Mao, X.; Ma, Y.; Zhang, A.; Zhang, L.; Zen, L.; Liu G. Anal. Chem. 2009, 81, 1660– 1668. (10) Mdluli, P.; Tetyana, P.; Sosibo, N.; Walt, H. V.; Mlambo, M.; Skepu, A.; Tshikhudo, R. Biosens. Bioelectron. 2014, 54, 1–6. (11) Deng, H.; Gao, Z. Anal. Chim. Acta 2015, 853, 30–45. (12) Nilsson, M.; Dahl, F.; Larsson, C.; Gullberg, M., Stenberg. J. Trends Biotechnol. 2006, 24, 83-88. (13) Nilsson, M.; Larsson, C.; Stenberg, J.; Göransson, J.; Grundberg, I.; Isaksson. M. Mol. Diagnostic. 2010, 117–132. (14) Nilsson, M.; Malmgren, H.; Samiotaki, M.; Kwiatkowski, M.; Chowdhary, B. P., Landegren, U. Science 1994, 265, 2085–2088. (15) Nilsson, M.; Krejci, K.; Koch, J.; Kwiatkowski, M.; Gustavsson, P.; Landegren, U. Nat. Genet. 1997, 16, 252–255. (16) Luo, J.; Bergstrom, D. E.; Barany, F. Nucleic Acids Res. 1996, 24, 3071–3078. (17) Dahl, F.; Baner, J.; Gullberg, M.; Mendel-Hartvig, M.; Landegren, U.; Nilsson, M. Proc. Natl. Acad. Sci. USA 2004, 101, 4548–4553. (18) Engström, A, Gómez de la Torre, Z. T.; Strømme, M.; Nilsson, M.; Herthnek, D.; PloS One 2004, 4, e62015. (19) Engström, A.; Morcillo, N.; Impriale, B.; Hoffner, S. E.; Jureen, P. J. Clin. Microbiol. 2012, 50, 2026-2033. (20) Jureen, P.; Engstrand, L.; Eriksson, S.; Alderborn, A.; Krabbe, M.; Hoffner, S. E. J. Clin. Microbiol. 2006, 44, 1925–1929. (21) Zuker, M. Nucleic Acids Res. 2003, 31, 3406–3415. (22) Jarvius, J.; Melin, J.; Go, J; Stenberg, J.; Fredriksson, S.; Gonzalez-Rey, C.; Bertilsson S. Nat. Methods 2006; 725–727. (23) Frens, G. Nat. Phys. Sci. 1973, 241, 20–22. (24) Schneider, C. A, Rasband, W. S.; Eliceiri, K. W. Nat. Methods. 2012, 9, 671-675. (25) Posthuma-Trumpie, G.; Korf, J.; Amerongen, A. V. Anal. Bioanal. Chem. 2009, 393, 569-582. (26) Ke, R.; Zorzet, A.; Göransson, J.; Lindegren, G.; Sharifi-Mood, B.; Chinikar, S.; Mardani, M.; Mirazimi, A.; Nilsson, M. J. Clin. Microbiol. 2001, 49, 4279–4285.


18

Page 19 of 21

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


438

Tables

439

Table 1. Genotypic information of the clinical MTB strains used in the study Strain ID rpoB genotype katG genotype 2 S531L (TCG/TTG) S315T (AGC/ACC) 4 S531L (TCG/TTG) S315T (AGC/ACC) 8 S531L (TCG/TTG) S315T (AGC/ACC) 9 S531L (TCG/TTG) S315T (AGC/ACC) 12 S531L (TCG/TTG) S315T (AGC/ACC) 13 S531L (TCG/TTG) WT 17 S531L (TCG/TTG) S315T (AGC/ACC) 19 WT WT 20 WT WT 21 WT WT

440


19


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48

441

Page 20 of 21

Table 2. Oligonucleotides used in this study Name

Sequence (5' --> 3')

Oligo ID S01233 S01234 S01237 S01239 S01235 S01236

rpoB 531 wt AtagrpoB 531 TTG AtagkatG 315 wt AtagkatG 315 ACC AtagTB-control oligo_v1 TB-Gold Oligo_v1

AAAAAAAAAAAAAAAGATCACACTTACGGAACAGC AAAAAAAAAAAAAAAGATCTAACGCACGGGAACTC AAAAAAAAAAAAAAACTGAGAGTTCGATGACCTGT AAAAAAAAAAAAAAAAATGCTCGGGAAGGCTACTC ATAGTGTCTTACTTAAAAAAAAAA GTAAGACACTATTACTGAGGAGAAAAAAAAAA

S00448

katG 315 wt

TGGTGATCGCGTCCTTACCACAGGTCATCGAACTCTCAGGTGTAT GCAGCTCCTCAGTAATAGTGTCTTACATACGACCTCGATGCCGC

S00565

katG 315 ACC

TGGTGATCGCGTCCTTACCGAGTAGCCTTCCCGAGCATTGTGTATG CAGCTCCTCAGTAATAGTGTCTTACATACGACCTCGATGCCGG

Padlock probe

S00592

rpoB 531 wt RS Popeye2

Padlock probe

S00228

rpoB 531 TTG RS v1

GGCGCTGGGGTTGCTGTTCCGTAAGTGTGATCGTGTATGCAGCTC CTCAGTAATAGTGTCTTACTGGTTGACCCACAAGTTTTTCCGACTG TC GGCGCTGGGGGAGTTCCCGTGCGTTAGATCGTGTATGCAGCTCCT CAGTAATAGTGTCTTACGCGCCGACTGTT

L11783

TB rpoB CO RS

L11860

katG CO

S00244 S00166 L12879

BNL_RO_AluI AluI RO TB rpoB SW RS wt v2

L11801

TB rpoB SW RS mut

L12721

katG SW wt v2

L12560

katG 315 ACC target

CTCTCTCTCTCTCTCTCTCTGTCCGCGACGTGCACCCGTCGCACTA CGGCCGGATGTGCC CTCTCTCTCTCTCTCTCTCTTTCCAGCCCAAGCCCATCTGCTCCAGC GGAGCAGCCTCGGGTTC GTGTATGCAGCTCCTCAGTA TACTGAGGAGCTGCATACAC GGCACATCCGGCCGTAGTGCGACGGGTGCACGTCGCGGACCCTCA CGTGACAGACCGCCGGGCCCCAGCGCCGACAGTCGGCGCTTGTGG GTCAACCCCGACAGCGG GGCACATCCGGCCGTAGTGCGACGGGTGCACGTCGCGGACCTCCA GCCCGGCACGCTCACGTGACAGACCGCCGGGCCCCAGCGCCAAC AGTCGGCGCTTGTGGGTCAACCCCGACAGCGGGTTGTT GAACCCGAGGCTGCTCCGCTGGAGCAGATGGGCTTGGGCTGGAA GAGCTCGTATGGTAAGGACGCGATCACCAGCGGCATCGAGGTCGT ATG GAACCCGAGGCTGCTCCGCTGGAGCAGATGGGCTTGGGCTGGAA GAGCTCGTATGGCACCGGAACCGGTAAGGACGCGATCACCACCG GCATCGAGGTCGTATGGAC

Description Strip oligonucleotide Strip oligonucleotide Strip oligonucleotide Strip oligonucleotide Strip oligonucleotide AuNP-oligonucleotide conjugate Padlock probe

5' modification Biotin Biotin Biotin Biotin

3' modification

Biotin Thiol

Padlock probe Capture oligonucleotide

Biotin

Capture oligonucleotide

Biotin

Restriction oligonucleotide Restriction oligonucleotide Synthetic target Synthetic target Synthetic target Synthetic target

20 ACS Paragon Plus Environment

Page 21 of 21

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

442 443 444


TOC

445


21

Proficient Detection of Multi-Drug-Resistant ... - ACS Publications

Recommend Documents